Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLC

Alice Shaw, MD, PhD, director of Thoracic Oncology at Massachusetts General Hospital, discussed the efficacy results from a recent trial investigating lorlatinib as treatment for patients with anaplastic lymphoma kinase-positive (ALK) non–small cell lung cancer that had failed other treatments prior, including crizotinib (Xalkori) and other multiple ALK tyrosine-kinase inhibitors. Promising results were found in a group that did not respond to prior treatments of crizotinib. In this group, there was a response rate of about 70%. There were also responses in a group of patients that had failed prior therapies with second generation inhibitors. The response rate for this group was 35-40%, and the median PFS was around 5.5-7 months. For more resources and information regarding current advances in lung cancer: http://www.targetedonc.com/resource-c...